Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMR NASDAQ:OCGN NASDAQ:RAPT NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$4.87+13.8%$3.93$1.61▼$9.50$403.13M14.13 million shs5.73 million shsOCGNOcugen$1.77$1.16$0.52▼$1.90$517.38M4.26.52 million shs12.13 million shsRAPTRapt Therapeutics$30.14+3.6%$15.09$5.67▼$31.76$498.46M0.23273,758 shs532,580 shsZNTLZentalis Pharmaceuticals$1.61-3.0%$1.56$1.01▼$4.44$116.14M1.77649,711 shs739,723 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%-4.32%+25.84%+55.10%-22.58%OCGNOcugen0.00%+21.23%+71.84%+83.23%+82.47%RAPTRapt Therapeutics0.00%+14.25%+136.76%+270.95%+67.44%ZNTLZentalis Pharmaceuticals0.00%+3.87%-9.04%+28.80%-51.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$4.87+13.8%$3.93$1.61▼$9.50$403.13M14.13 million shs5.73 million shsOCGNOcugen$1.77$1.16$0.52▼$1.90$517.38M4.26.52 million shs12.13 million shsRAPTRapt Therapeutics$30.14+3.6%$15.09$5.67▼$31.76$498.46M0.23273,758 shs532,580 shsZNTLZentalis Pharmaceuticals$1.61-3.0%$1.56$1.01▼$4.44$116.14M1.77649,711 shs739,723 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%-4.32%+25.84%+55.10%-22.58%OCGNOcugen0.00%+21.23%+71.84%+83.23%+82.47%RAPTRapt Therapeutics0.00%+14.25%+136.76%+270.95%+67.44%ZNTLZentalis Pharmaceuticals0.00%+3.87%-9.04%+28.80%-51.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 2.80Moderate Buy$16.71243.21% UpsideOCGNOcugen 2.50Moderate Buy$6.00238.98% UpsideRAPTRapt Therapeutics 2.55Moderate Buy$23.50-22.03% DownsideZNTLZentalis Pharmaceuticals 2.33Hold$5.84262.73% UpsideCurrent Analyst Ratings BreakdownLatest ZNTL, RAPT, OCGN, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/2/2025LRMRLarimar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$26.00 ➝ $21.009/30/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$10.00 ➝ $7.009/30/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$15.00 ➝ $11.009/27/2025LRMRLarimar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RAPTRapt TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZNTLZentalis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025RAPTRapt TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$16.00 ➝ $37.009/25/2025RAPTRapt TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/19/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/22/2025RAPTRapt TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/AOCGNOcugen$4.05M127.75N/AN/A$0.10 per share17.70RAPTRapt Therapeutics$1.53M325.83N/AN/A$11.51 per share2.62ZNTLZentalis Pharmaceuticals$67.43M1.72N/AN/A$4.73 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)OCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$165.84M-$2.26N/AN/AN/AN/A-51.62%-40.28%11/11/2025 (Estimated)Latest ZNTL, RAPT, OCGN, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025LRMRLarimar Therapeutics-$0.40N/AN/AN/AN/AN/A8/14/2025Q2 2025LRMRLarimar Therapeutics-$0.47-$0.41+$0.06-$0.41N/AN/A8/7/2025Q2 2025RAPTRapt Therapeutics-$0.61-$0.65-$0.04-$0.65N/AN/A8/6/2025Q2 2025ZNTLZentalis Pharmaceuticals-$0.56-$0.37+$0.19-$0.37N/AN/A8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A5.465.46OCGNOcugen9.181.831.83RAPTRapt TherapeuticsN/A13.2513.25ZNTLZentalis PharmaceuticalsN/A7.997.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%OCGNOcugen10.27%RAPTRapt Therapeutics99.09%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics4.50%OCGNOcugen4.42%RAPTRapt Therapeutics2.36%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics3082.78 million79.05 millionOptionableOCGNOcugen80292.30 million279.39 millionOptionableRAPTRapt Therapeutics8016.54 million16.15 millionOptionableZNTLZentalis Pharmaceuticals16072.14 million70.76 millionOptionableZNTL, RAPT, OCGN, and LRMR HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $5.84 Average Price Target from AnalystsSeptember 28, 2025 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 25, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Goldman Sachs Group Inc.September 24, 2025 | marketbeat.comAcadian Asset Management LLC Has $4.24 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTLSeptember 16, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comZentalis Pharmaceuticals Grants Stock Options to New Employees as Part of Inducement PlanSeptember 2, 2025 | quiverquant.comQZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comZentalis Pharmaceuticals Announces New Chief Legal OfficerAugust 26, 2025 | msn.comZentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate SecretaryAugust 26, 2025 | globenewswire.comGuggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)August 19, 2025 | theglobeandmail.comZentalis Pharmaceuticals (ZNTL) Gets a Buy from TD CowenAugust 18, 2025 | theglobeandmail.comZentalis (ZNTL) Q2 Loss Narrows 70%August 18, 2025 | theglobeandmail.comZentalis price target lowered to $5 from $6 at Wells FargoAugust 8, 2025 | msn.comZentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational ProgressAugust 6, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the companyJuly 24, 2025 | finance.yahoo.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHere's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn SituationJune 26, 2025 | finance.yahoo.comZentalis Pharmaceuticals shareholders elect three directors at annual meetingJune 20, 2025 | investing.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZNTL, RAPT, OCGN, and LRMR Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$4.87 +0.59 (+13.79%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.83 -0.04 (-0.82%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Ocugen NASDAQ:OCGN$1.77 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.78 +0.01 (+0.85%) As of 10/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Rapt Therapeutics NASDAQ:RAPT$30.14 +1.04 (+3.57%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$29.19 -0.95 (-3.15%) As of 10/3/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyZentalis Pharmaceuticals NASDAQ:ZNTL$1.61 -0.05 (-3.01%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 10/3/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
